Log in

NASDAQ:ODT - Odonate Therapeutics Stock Price, Forecast & News

$31.34
-0.41 (-1.29 %)
(As of 02/27/2020 04:59 AM ET)
Today's Range
$30.56
Now: $31.34
$32.15
50-Day Range
$26.95
MA: $30.82
$35.25
52-Week Range
$15.67
Now: $31.34
$43.75
Volume123,700 shs
Average Volume83,803 shs
Market Capitalization$1.00 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ODT
CUSIPN/A
Phone858-731-8180

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.06 per share

Profitability

Net Income$-111,820,000.00

Miscellaneous

Employees117
Market Cap$1.00 billion
Next Earnings Date4/23/2020 (Estimated)
OptionableNot Optionable

Receive ODT News and Ratings via Email

Sign-up to receive the latest news and ratings for ODT and its competitors with MarketBeat's FREE daily newsletter.


Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions

What is Odonate Therapeutics' stock symbol?

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

How were Odonate Therapeutics' earnings last quarter?

Odonate Therapeutics Inc (NASDAQ:ODT) issued its earnings results on Thursday, February, 20th. The company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.02) by $0.11. View Odonate Therapeutics' Earnings History.

When is Odonate Therapeutics' next earnings date?

Odonate Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for Odonate Therapeutics.

What price target have analysts set for ODT?

2 equities research analysts have issued 1 year price objectives for Odonate Therapeutics' shares. Their forecasts range from $26.00 to $26.00. On average, they expect Odonate Therapeutics' share price to reach $26.00 in the next twelve months. This suggests that the stock has a possible downside of 17.0%. View Analyst Price Targets for Odonate Therapeutics.

What is the consensus analysts' recommendation for Odonate Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Odonate Therapeutics.

Has Odonate Therapeutics been receiving favorable news coverage?

Media stories about ODT stock have been trending positive recently, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Odonate Therapeutics earned a media sentiment score of 2.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Odonate Therapeutics.

Are investors shorting Odonate Therapeutics?

Odonate Therapeutics saw a decline in short interest in February. As of February 14th, there was short interest totalling 1,120,000 shares, a decline of 8.9% from the January 30th total of 1,230,000 shares. Based on an average daily volume of 95,700 shares, the days-to-cover ratio is presently 11.7 days. Approximately 3.8% of the shares of the stock are sold short. View Odonate Therapeutics' Current Options Chain.

Who are some of Odonate Therapeutics' key competitors?

What other stocks do shareholders of Odonate Therapeutics own?

Who are Odonate Therapeutics' key executives?

Odonate Therapeutics' management team includes the folowing people:
  • Mr. Kevin C. Tang, Chairman & CEO (Age 52)
  • Mr. John G. Lemkey, Chief Operating Officer (Age 38)
  • Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 65)
  • Mr. Michael S. Hearne, CFO & Principal Accounting Officer (Age 57)
  • Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 43)

When did Odonate Therapeutics IPO?

(ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager.

Who are Odonate Therapeutics' major shareholders?

Odonate Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (4.14%), Franklin Resources Inc. (3.71%), Driehaus Capital Management LLC (2.07%), State Street Corp (0.75%), Pictet Asset Management Ltd. (0.61%) and Geode Capital Management LLC (0.52%). Company insiders that own Odonate Therapeutics stock include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Institutional Ownership Trends for Odonate Therapeutics.

Which major investors are selling Odonate Therapeutics stock?

ODT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., Oxford Asset Management LLP, Goldman Sachs Group Inc., California Public Employees Retirement System, Chartwell Investment Partners LLC, Spark Investment Management LLC and Bank of America Corp DE. View Insider Buying and Selling for Odonate Therapeutics.

Which major investors are buying Odonate Therapeutics stock?

ODT stock was purchased by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Pictet Asset Management Ltd., State Street Corp, Janus Henderson Group PLC, Virtus ETF Advisers LLC, AQR Capital Management LLC, UBS Group AG and Bank of New York Mellon Corp. Company insiders that have bought Odonate Therapeutics stock in the last two years include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Insider Buying and Selling for Odonate Therapeutics.

How do I buy shares of Odonate Therapeutics?

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Odonate Therapeutics' stock price today?

One share of ODT stock can currently be purchased for approximately $31.34.

How big of a company is Odonate Therapeutics?

Odonate Therapeutics has a market capitalization of $1.00 billion. The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe.View Additional Information About Odonate Therapeutics.

What is Odonate Therapeutics' official website?

The official website for Odonate Therapeutics is http://www.odonate.com/.

How can I contact Odonate Therapeutics?

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]


MarketBeat Community Rating for Odonate Therapeutics (NASDAQ ODT)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  136 (Vote Outperform)
Underperform Votes:  190 (Vote Underperform)
Total Votes:  326
MarketBeat's community ratings are surveys of what our community members think about Odonate Therapeutics and other stocks. Vote "Outperform" if you believe ODT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ODT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel